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ABSTRACT
Background: This study examined the prevalence of hypogonad-
ism, its clinical and genetic risk factors, and its relationship to ad-
verse health outcomes (AHOs) in North American testicular cancer
survivors (TCS) after modern platinum-based chemotherapy. Patients
and Methods: Eligible TCS were,55 years of age at diagnosis and
treated with ﬁrst-line platinum-based chemotherapy. Participants
underwent physical examinations and completed questionnaires
regarding 15 AHOs and health behaviors. Hypogonadism was
deﬁned as serum testosterone levels #3.0 ng/mL or use of testos-
terone replacement therapy. We investigated the role of 2 single
nucleotide polymorphisms (rs6258 and rs12150660) in the sex
hormone–binding globulin (SHBG) locus implicated in increased
hypogonadism risk in the general population. Results: Of 491 TCS
(median age at assessment, 38.2 years; range, 18.7–68.4 years), 38.5%
had hypogonadism. Multivariable binary logistic regression analysis
identiﬁed hypogonadism risk factors, including age at clinical evalua-
tion (odds ratio [OR], 1.42 per 10-year increase; P5.006) and body
mass index of 25 to ,30 kg/m2 (OR, 2.08; P5.011) or $30 kg/m2
(OR, 2.36; P5.005) compared with ,25 kg/m2. TCS with $2 risk
alleles for the SHBG SNPs had a marginally signiﬁcant increased
hypogonadism risk (OR, 1.45; P5.09). Vigorous-intensity physical
activity appeared protective (OR, 0.66; P5.07). Type of cisplatin-
based chemotherapy regimen and socioeconomic factors did not
correlate with hypogonadism. Compared with TCS without hypo-
gonadism, those with hypogonadism were more likely to report $2
AHOs (65% vs 51%; P5.003), to take medications for hypercho-
lesterolemia (20.1% vs 6.0%; P,.001) or hypertension (18.5% vs
10.6%; P5.013), and to report erectile dysfunction (19.6% vs
11.9%; P5.018) or peripheral neuropathy (30.7% vs 22.5%; P5.041).
A marginally signiﬁcant trend for increased use of prescription
medications for either diabetes (5.8% vs 2.6%; P5.07) or anxiety/
depression (14.8% vs 9.3%; P5.06) was observed. Conclusions: At
a relatively young median age, more than one-third of TCS have
hypogonadism, which is signiﬁcantly associated with increased car-
diovascular disease risk factors, and erectile dysfunction. Providers
should screen TCS for hypogonadism and treat symptomatic patients.
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Background
Testicular cancer is the most common cancer among
young men (age 18–39 years).1 Currently, .95% of pa-
tients are cured of the disease.2 Although some patients
with stage I disease are cured with orchiectomy only,
those with advanced or recurrent disease will typi-
cally require cisplatin-based chemotherapy. Although
testicular cancer survivors (TCS) can now expect to live
for .40 years after diagnosis,3 they are at risk for short-
and long-term complications related to cancer ther-
apy, including hypogonadism.4
Hypogonadism and its health eﬀects have been largely
studied in the general population in older men, because
testosterone levels decrease with aging.5–8 Hypogonadism
has been linked to obesity, high cholesterol levels, car-
diovascular disease (CVD), and decreased bone mineral
density.9,10 Recent genetic investigations in the general
population have identiﬁed 2 single nucleotide polymor-
phisms (SNPs) in the sex hormone–binding globulin gene
(SHBG) through genome-wide association studies associ-
ated with increased risk for hypogonadism.11 No study,
however, has examined the prevalence of hypogonad-
ism in North American TCS and its relationship to
adverse health outcomes (AHOs).
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Most TCS have had one testicle (or both) surgically
removed and have received chemotherapy that can
damage the function of the remaining testicle, and thus
are already at elevated risk for hypogonadism compared
with the general population. In addition, an inherently
increased risk may be due to testicular dysgenesis syn-
drome, a constellation of conditions proposed to also
elevate risk of testicular cancer.12–14
This study examined the prevalence of AHOs in re-
lationship to hypogonadism among TCS enrolled in the
PlatinumStudy, amulticenterNorth American investigation
of the long-term eﬀects of cisplatin-based chemotherapy.
The role of SHBG gene polymorphisms in hypogonadism
risk among TCS are also investigated for the ﬁrst time.
Patients and Methods
Participants
The Platinum Study protocol evaluated late consequences
of platinum-based chemotherapy and was approved by
the Institutional Review Boards at all participating insti-
tutions.15 Each study participant provided written in-
formed consent allowing access to their medical records
since their cancer diagnosis. Eligibility criteria included
conﬁrmed diagnosis of germ cell tumor (GCT), age
,55 years at diagnosis, treatment with ﬁrst-line platinum-
based chemotherapy, no salvage chemotherapy, no
radiotherapy, and no antecedent chemotherapy for
another primary cancer. All participants were disease-free
at the time of clinical evaluation and were undergoing
routine follow-up at the participating site. The ﬁrst 491
consecutively enrolled TCS for whom funding was avail-
able to measure serum testosterone were included in this
analysis. Participants in this analysis were similar to the
ﬁrst 1,214 survivors enrolled in the Platinum Study16 in
terms of age at testicular cancer diagnosis (P5.81), age at
clinical evaluation for the Platinum Study (P5.30), and
other clinical and sociodemographic characteristics (sup-
plemental eTable 1, availablewith this article at JNCCN.org).
Data on the prevalence ofmetabolic syndrome and its risk
factors in this cohort have been previously described.17
Assessments
Patient-Reported Health Outcomes and
Lifestyle Behaviors
TCS completed a questionnaire regarding health outcomes,
lifestyle behaviors, and current prescription medica-
tions with indications (including antihypertensive, di-
abetic, and lipid-lowering medications). Each of the
following conditions was considered an AHO (deﬁnitions
provided in supplemental eTable 2): hypercholesterol-
emia and on prescription medication, hypertension and
on prescription medication, erectile dysfunction (ED),
diabetes and on prescription medication, psychotropic
prescription medications for anxiety and/or depression,
CVD, peripheral vascular disease, thromboembolic disease,
renal disease, peripheral neuropathy,Raynaudphenomenon,
benign thyroid disease, tinnitus, hearing impairment, and
problems with balance/vertigo/dizziness. Demographic
information included age at cancer diagnosis and at
clinical evaluation, race, education, employment, and
marital status. Smoking status was categorized as current,
former, or never-smoker. Physical activity was reported
as the average time per week engaged in various forms
of exercise, using validated questionnaires.18 Moderate- and
vigorous-intensity physical activity were deﬁned as partici-
pating in at least 1 activity per week with a metabolic equiv-
alent (MET) of 3 to ,6 METs or $6 METs, respectively.16,19,20
Data Collection From Medical Records
Study staﬀ abstracted data according to a standardized
protocol.15,16 Collected data included diagnosis date,
histology, and site of GCT, and the name, dose, dates of
administration, number of cycles, and cumulative dose
for each cytotoxic drug. All data were entered into the
eClinical system (www.eClinicalWorks.com), supported
by the study coordinating center.
Clinical Evaluation
TCS underwent a brief physical examination, which in-
cluded measurement of height and weight. Body mass
index (BMI) was calculated as kg/m2. Blood samples were
drawn and time of collection was recorded, and the
samples were then frozen and shipped to the central
laboratory. Serum levels of testosterone were mea-
sured using commercial assays. Hypogonadism was
deﬁned using the FDA deﬁnition (serum testosterone level
#3.0 ng/mL)21 or use of testosterone replacement therapy.
DNA Genotyping and Imputation
DNA was extracted from blood samples collected
at clinical evaluation. SNPs were genotyped on the
HumanOmniExpressExome-8 BeadChip Kit (Illumina, Inc.)
at the RIKEN Center for Integrative Medical Sciences.
Because the SNPs of interest are not called on this chip, we
performed genotype imputation following standard quality
control measures as previously described.22 Imputation
was performed on the University ofMichigan Imputation
Server23with the followingparameters: 1000GenomesPhase
1 (version 3) SHAPEIT2 (no singletons) reference panel,
SHAPEIT phasing, and the EUR (European) population.
SNP calls were converted to risk allele dosage format.
Statistical Analyses
Data were summarized with median (ranges) for con-
tinuous variables and proportions for categorical vari-
ables in 2 TCS subgroups deﬁned by the presence or
absence of hypogonadism. Variables in the 2 groups were
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compared using the Pearson chi-square and 2-sided
Wilcoxon rank sum tests for categorical and continuous
variables, respectively. To determine factors associated
with hypogonadism in TCS, variables that were signif-
icantly diﬀerent between the 2 groups with regard to
clinical, sociodemographic, and other characteristics
were included in the multivariable binary logistic re-
gression analysis. Adjusted odds ratios (ORs), 95% CIs,
and P values were reported. Cumulative number of risk
alleles in SHBG was also included in the multivariable
model due to evidence for its role in the determination of
serum testosterone concentrations in the general male
population.11 All statistical analyses were conducted using
SAS 9.4 (SAS Institute Inc.). All tests were 2-sided, with
P,.05 considered statistically signiﬁcant.
Results
Population Characteristics of TCS
A total of 491 TCS were assessed, with a median age at
clinical evaluation of 38.2 years (Table 1). In all, 189 TCS
(38.5%) met criteria for hypogonadism. TCS with hypo-
gonadism were signiﬁcantly older at clinical evaluation
than those without hypogonadism (median age, 42.6 vs
36.5 years; P,.001). Most TCS received bleomycin/
etoposide/cisplatin (BEP; 55.4%) or etoposide/cisplatin
(EP; 32.4%), but hypogonadism prevalence did not dif-
fer by treatment regimen (P5.95) or cumulative dose of
cisplatin or bleomycin (P5.99 and .56, respectively). TCS
with hypogonadism had a signiﬁcantly higher prevalence
of being overweight or obese (83.1% vs 69.2%; P,.001),
and were less likely to participate in vigorous-intensity
physical activity (56.1% vs 72.5%; P,.001) compared with
those without hypogonadism.
Factors Associated With Hypogonadism in TCS
In multivariable binary logistic regression analysis, age at
clinical evaluation (OR, 1.42 per 10-year increase in age;
95% CI, 1.10–1.83; P5.006) and being overweight (BMI,
25 to ,30 kg/m2; OR, 2.08; 95% CI, 1.18–3.66; P5.011) or
obese (BMI, $30 kg/m2; OR, 2.36; 95% CI, 1.29–4.31;
P5.005) were signiﬁcantly associated with increased risk
for hypogonadism (Table 2). Although signiﬁcant in bi-
variate analysis, vigorous-intensity physical activity was
only marginally associated with reduced hypogonad-
ism risk (OR, 0.66; 95% CI, 0.41–1.04; P5.07) after adjusting
for other independent variables in the model. TCS with 2
or 3 risk alleles had a trend for increased risk of hypo-
gonadism compared with TCS with no or 1 risk allele in
multivariable analysis (OR, 1.45; 95% CI, 0.95–2.24; P5.09).
Association Between Hypogonadism and AHOs
Among all 15 AHOs included in the survey, 28% of TCS
with hypogonadism reported $4 AHOs compared with
16% of those without hypogonadism (Figure 1), and TCS
with hypogonadism were less likely to report no or only
one AHO (35%) compared with those without (49%)
(P5.002). Associations between speciﬁc AHOs and
hypogonadism are shown in Table 3. Compared with
TCS without hypogonadism, those with hypogonadism
were signiﬁcantly more likely to take medications for
hypercholesterolemia (20.1% vs 6.0%; P,.001), hyper-
tension (18.5% vs 10.6%; P5.013), and ED (19.6% vs
11.9%; P5.018), with a marginal trend toward increased
use of prescription medications for either diabetes (5.8%
vs 2.6%; P5.07) or anxiety/depression (14.8% vs 9.3%;
P5.06). TCS with hypogonadism were also signiﬁcantly
more likely to report symptoms of moderate or severe
peripheral neuropathy (30.7% vs 22.5%; P5.041) com-
pared with those without hypogonadism. As expected,
no associations were observed between hypogonadism
and several of the AHOs, such as tinnitus and hearing
loss.
Association of Genetic Variants in SHBG
With Hypogonadism
We assessed the association of 2 SNPs (rs6258 and
rs12150660) in the SHBG locus previously implicated in
increased hypogonadism risk in the general population.11
SNPs rs12150660 and rs6258 showed, respectively, high
imputation quality (R2, 0.99 and 0.87), high call rate
(.99.7% and .99.8%), and perfect Hardy-Weinberg equi-
librium (P5.98 and .97). Because rs6258 is a rare variant
(minor allele frequency, 0.69%), there were no homo-
zygous minor patients and only 7 heterozygous patients
in the cohort. Both SNPs displayed eﬀect sizes simi-
lar to those reported previously in the general pop-
ulation (rs6258: OR, 1.6; P5.5; rs12150660: OR, 0.79;
P5.28). When the risk for hypogonadism was analyzed
according to the cumulative number of risk alleles for
rs12150660 (G) and rs6258 (T) (Figure 2), OR per each
additional risk allele was 1.26 (95% CI, 0.91–1.76; P for
trend 5.17).
Discussion
To date, this is the largest investigation of the prevalence
of hypogonadism and associated AHOs among North
American TCS after treatment with modern cisplatin-
based chemotherapy. It is also the ﬁrst series to in-
vestigate the inﬂuence of genetic variants in the SHBG
gene on hypogonadism risk in TCS. At a median age of
only 38 years at clinical evaluation,.38% of TCS had low
testosterone levels or were on testosterone replacement
therapy. Signiﬁcant risk factors included increasing age
and BMI. Although vigorous-intensity physical activity
appeared protective and genetic variants in SHBG may
have inﬂuenced hypogonadism risk, results were of
borderline signiﬁcance.
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Table 1. Patient Characteristics
Characteristic
All Patients
n (%)
Hypogonadism
P ValueaPresent, n (%) Absent, n (%)
Total 491 (100) 189 (100) 302 (100)
Median age at testicular cancer diagnosis (range), y 30.6 (15.4–49.9) 33.5 (15.9–49.9) 29.6 (15.4–49.7) <.001
Clinical characteristics
Age at clinical evaluation for Platinum Study
Median (range), y 38.2 (18.7–68.4) 42.6 (20.2–68.4) 36.5 (18.7–68.1) <.001
,30 y 101 (20.6) 29 (15.3) 72 (23.9)
<.001
30–39 y 168 (34.2) 51 (27.0) 117 (38.7)
40–49 y 139 (28.3) 63 (33.3) 76 (25.2)
$50 y 82 (16.7) 46 (24.3) 36 (11.9)
Missing 1 (0.2) 0 1 (0.3)
Tumor histology
Seminoma 130 (26.5) 63 (33.3) 67 (22.2)
.007
Nonseminoma/Mixed 361 (73.5) 126 (66.7) 235 (77.8)
Tumor site
Testis 438 (89.2) 172 (91.0) 266 (88.1)
.32
Extragonadal 53 (10.8) 17 (9.0) 36 (11.9)
Tumor stage
I 128 (26.1) 50 (26.5) 78 (25.8)
.66II 189 (38.5) 74 (39.2) 115 (38.1)
III 111 (22.6) 38 (20.1) 73 (24.2)
Not stated 63 (12.8) 27 (14.3) 36 (11.9)
Cumulative dose of cisplatin, mg/m2
,300 28 (5.7) 10 (5.3) 18 (6.0)
.99
300 155 (31.6) 60 (31.7) 95 (31.5)
301–399 17 (3.5) 7 (3.7) 10 (3.3)
400 265 (54.0) 103 (54.5) 162 (53.6)
.400 23 (4.7) 8 (4.2) 15 (5.0)
Received carboplatin 3 (0.6) 1 (0.5) 2 (0.7)
Cumulative dose of bleomycin, IU
0 198 (40.3) 72 (38.1) 126 (41.7)
.56
.0–180,000 37 (7.5) 18 (9.5) 19 (6.3)
181,000–270,000 183 (37.3) 69 (36.5) 114 (37.7)
271,000–360,000 72 (14.7) 30 (15.9) 42 (13.9)
.360,000 1 (0.2) 0 (0) 1 (0.3)
(continued on next page)
Abbreviations: BEP, bleomycin/etoposide/cisplatin; EP, etoposide/cisplatin; METs, metabolic equivalents.
aP value from Wilcoxon test for continuous variables or chi-square for categorical variables. Missing values were not included in P value calculation. Statistically
signiﬁcant P values are in bold.
bOf survivors who received BEP, 170 and 92 were administered BEP x 3 and BEP x 4, respectively.
cAll 159 survivors received EP x 4.
dThis category includes 15 patients treated with ifosfamide/etoposide/cisplatin (VIP regimen), 3 patients treated with carboplatin, and 41 patients with other
chemotherapy regimens.
eNonwhite race includes: Asian, 19 (3.9%); black/African American, 6 (1.2%); American Indian, 1 (0.2%); more than one race, 9 (1.8%); and declined to answer/other/
unknown, 40 (8.1%).
fVigorous- and moderate-intensity physical activity groups are not mutually exclusive. Nine different activities were surveyed in the Platinum Study, some were moderate-
intensity and some vigorous-intensity. If a subject reported that he spent 1 hour walking per week (ie, a moderate-intensity activity) and 30 minutes running per week (ie, a
vigorous-intensity activity), he was included as a yes for both “any moderate” and “any vigorous” activity19,20; 3 survivors did not provide data on physical activity.
gOne patient without hypogonadism was missing a body mass index value and was not included in the calculation of P value.
hSamples from these patients had not been processed in time to be included in the genotyping performed for this study and are not included in the calculation of P value.
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Table 1. Patient Characteristics (cont.)
Characteristic
All Patients
n (%)
Hypogonadism
P ValueaPresent, n (%) Absent, n (%)
Platinum-based chemotherapy
BEPb 272 (55.4) 106 (56.1) 166 (55.0)
.95EPc 159 (32.4) 60 (31.7) 99 (32.8)
Otherd 59 (12.0) 22 (11.6) 37 (12.3)
Not stated 1 (0.2) 1 (0.5) 0 (0)
Time since last chemotherapy
Median (range), y 4.7 (0.4–24.2) 4.9 (1.0–23.7) 4.4 (0.4–24.2) .17
,2 y 80 (16.3) 30 (15.9) 50 (16.6)
.82
2–5 y 219 (44.6) 82 (43.4) 137 (45.4)
6–9 y 75 (15.3) 28 (14.8) 47 (15.6)
$10 y 113 (23.0) 48 (25.4) 65 (21.5)
Not stated 4 (0.8) 1 (0.5) 3 (1.0)
Sociodemographic characteristics
Race
White 416 (84.7) 160 (84.7) 256 (84.8)
.97
Nonwhitee 75 (15.3) 29 (15.3) 46 (15.2)
Marital status
Married/Living as married 295 (60.1) 125 (66.1) 170 (56.3)
.038
Not married/prefer not to say 196 (39.9) 64 (33.9) 132 (43.7)
Education
Less than college graduate 60 (12.2) 20 (10.6) 40 (13.2)
.67Some college, college graduate 318 (64.8) 125 (66.1) 193 (63.9)
Postgraduate level 104 (21.2) 41 (21.7) 63 (20.9)
Other/Prefer not to say 9 (1.8) 3 (1.6) 6 (2.0)
Employment status
Not employed/prefer not to say 58 (11.8) 25 (13.2) 33 (10.9)
.44
Employed 433 (88.2) 164 (86.8) 269 (89.1)
Health behaviors
Smoking status
Never-smoker 276 (56.2) 103 (54.5) 173 (57.3)
.75Former smoker 166 (33.8) 68 (36.0) 98 (32.5)
Current smoker 47 (9.6) 18 (9.5) 29 (9.6)
Not stated 2 (0.4) 0 (0) 2 (0.7)
(continued on next page)
Abbreviations: BEP, bleomycin/etoposide/cisplatin; EP, etoposide/cisplatin; METs, metabolic equivalents.
aP value from Wilcoxon test for continuous variables or chi-square for categorical variables. Missing values were not included in P value calculation. Statistically
signiﬁcant P values are in bold.
bOf survivors who received BEP, 170 and 92 were administered BEP x 3 and BEP x 4, respectively.
cAll 159 survivors received EP x 4.
dThis category includes 15 patients treated with ifosfamide/etoposide/cisplatin (VIP regimen), 3 patients treated with carboplatin, and 41 patients with other
chemotherapy regimens.
eNonwhite race includes: Asian, 19 (3.9%); black/African American, 6 (1.2%); American Indian, 1 (0.2%); more than one race, 9 (1.8%); and declined to answer/other/
unknown, 40 (8.1%).
fVigorous- and moderate-intensity physical activity groups are not mutually exclusive. Nine different activities were surveyed in the Platinum Study, some were moderate-
intensity and some vigorous-intensity. If a subject reported that he spent 1 hour walking per week (ie, a moderate-intensity activity) and 30 minutes running per week (ie, a
vigorous-intensity activity), he was included as a yes for both “any moderate” and “any vigorous” activity19,20; 3 survivors did not provide data on physical activity.
gOne patient without hypogonadism was missing a body mass index value and was not included in the calculation of P value.
hSamples from these patients had not been processed in time to be included in the genotyping performed for this study and are not included in the calculation of P value.
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Similar to ﬁndings in the general population24–28 and
in European studies of TCS,29–34 TCS with hypogonadism
in our study were more likely to report components of
metabolic syndrome than TCSwith normal testosterone
levels. In particular, they were at least 3 times more
likely to take medications for high cholesterol levels
(P,.001) and almost twice as likely to take medications
for high blood pressure (P5.013) and diabetes (P5.07).
These observations may explain ﬁndings in previous
studies that TCS treated with chemotherapy experience
up to a 7-fold increased risk for CVD, with upswings in risk
typically observed $10 years after therapy.35–39 Because
the median cohort follow-up time was ,5 years, we have
not yet observed an increase in cardiovascular events
among TCS with hypogonadism, but long-term follow-up
of all survivors is planned. The association between
hypogonadism and peripheral neuropathy was unex-
pected and may represent a chance ﬁnding. However, we
previously showed that peripheral sensory neuropathy
among TCS is associated with weight gain adjusted for
years since treatment (P5.004).40 Thus, it is possible that
TCS with signiﬁcant neuropathy may not be able to
Table 1. Patient Characteristics (cont.)
Characteristic
All Patients
n (%)
Hypogonadism
P ValueaPresent, n (%) Absent, n (%)
Average number of alcoholic drinks in past year
Rarely or never 99 (20.2) 43 (22.8) 56 (18.5)
.15
#4 per week 219 (44.6) 92 (48.7) 127 (42.1)
5 per week to 1 daily 109 (22.2) 33 (17.5) 76 (25.2)
$2 daily 58 (11.8) 21 (11.1) 37 (12.3)
Not stated 6 (1.2) 0 (0) 6 (2.0)
Moderate-intensity physical activity (3–6 METs)f
No 28 (5.7) 15 (7.9) 13 (4.3)
.09
Yes 460 (93.7) 173 (91.5) 287 (95.0)
Not stated 3 (0.6) 1 (0.5) 2 (0.7)
Vigorous-intensity physical activity ($6 METs)f
No 163 (33.2) 82 (43.4) 81 (26.8)
<.001
Yes 325 (66.2) 106 (56.1) 219 (72.5)
Not stated 3 (0.6) 1 (0.5) 2 (0.7)
Physical examination and genetic variants
Body mass indexg
Median (range), kg/m2 27.7 (18.0–52.8) 28.7 (18.0–47.7) 27.1 (19.6–52.8) <.001
,25 kg/m2 124 (25.3) 32 (16.9) 92 (30.5)
<.001
$25 kg/m2 366 (74.5) 157 (83.1) 209 (69.2)
Cumulative number of risk alleles in rs6258 and rs12150660 (SHBG)
0 or 1 176 (35.8) 62 (32.8) 114 (37.7)
.22
2 or 3 228 (46.4) 94 (49.7) 134 (44.4)
Not genotypedh 87 (17.7) 33 (17.5) 54 (17.9)
Abbreviations: BEP, bleomycin/etoposide/cisplatin; EP, etoposide/cisplatin; METs, metabolic equivalents.
aP value from Wilcoxon test for continuous variables or chi-square for categorical variables. Missing values were not included in P value calculation. Statistically
signiﬁcant P values are in bold.
bOf survivors who received BEP, 170 and 92 were administered BEP x 3 and BEP x 4, respectively.
cAll 159 survivors received EP x 4.
dThis category includes 15 patients treated with ifosfamide/etoposide/cisplatin (VIP regimen), 3 patients treated with carboplatin, and 41 patients with other
chemotherapy regimens.
eNonwhite race includes: Asian, 19 (3.9%); black/African American, 6 (1.2%); American Indian, 1 (0.2%); more than one race, 9 (1.8%); and declined to answer/other/
unknown, 40 (8.1%).
fVigorous- and moderate-intensity physical activity groups are not mutually exclusive. Nine different activities were surveyed in the Platinum Study, some were moderate-
intensity and some vigorous-intensity. If a subject reported that he spent 1 hour walking per week (ie, a moderate-intensity activity) and 30 minutes running per week (ie, a
vigorous-intensity activity), he was included as a yes for both “any moderate” and “any vigorous” activity19,20; 3 survivors did not provide data on physical activity.
gOne patient without hypogonadism was missing a body mass index value and was not included in the calculation of P value.
hSamples from these patients had not been processed in time to be included in the genotyping performed for this study and are not included in the calculation of P value.
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exercise adequately, and consequently develop obesity
that increases hypogonadism risk, as it does among men
in the general population.7 The prevalence of metabolic
syndrome in TCS and its risk factors have been reviewed
in detail elsewhere.17
In our investigation, the cumulative dose of cisplatin
did not correlate with the prevalence of hypogonadism.
Other studies41,42 have reported a higher prevalence of
hypogonadism in TCS who received higher doses of cis-
platin. Because most patients in the current series (89.1%)
received a cumulative cisplatin dose between 300 and
400mg/m2, thismay explain the lack of correlation observed.
Ohlsson et al11 recently performed a meta-analysis
of genome-wide association data in 14,429 men from 7
cohorts in the general population and identiﬁed 2 SNPs
at the SHBG locus as independently associated with
serum testosterone concentration. In our study, these
SNPs also appeared to aﬀect testosterone concentra-
tion but were of borderline statistical signiﬁcance. In
addition, although the magnitude of inﬂuence of these
genetic variants on serum testosterone concentration
(OR, 1.26 per additional risk allele) in TCS was some-
what less than reported in the general population (OR,
1.62 per additional risk allele), the 95% CIs overlapped
substantially. In addition, it is possible that other ge-
netic variants, possibly ones that predispose to testic-
ular dysgenesis syndrome (eg, INSL3 and LGR8),43–45
may be of higher importance in TCS. As pointed out by
Ohlsson et al,11 the eventual clinical use of these genetic
variantswill require further investigation. A critical question
is the extent to which these polymorphisms might also
inﬂuence the eventual development of CVD, and not only
mediate low testosterone levels. It is important to note that
the prevalence of hypogonadism was substantially higher
in our survivors (38.5%) compared with subjects included
in the meta-analysis by Ohlsson et al11 (13.5%) (Figure 2).
This is despite the fact that the median age of our TCS was
only 38 years at the time of clinical evaluation compared
with amean age of 61.7 years for those included in Ohlsson
et al.11 This places TCS at risk of the complications of
hypogonadism for many more decades than men without
a history of testicular cancer.
Studies of the eﬀect of testosterone replacement
therapy on metabolic abnormalities and CVD risk in
TCS are sparse. Investigations in middle-aged and
highly functioning older men with no cancer history
showed favorable eﬀects on lipid metabolism, bone
mineral density, muscle mass, and fat-free body mass.9,10
However, evidence regarding the eﬀect of testosterone
replacement on CVD risk has been conﬂicting,46 with
one clinical trial showing an unexpected increase in
adverse CVD events in older men treated with testos-
terone,47 but another series reporting no excess CVD
events.48 A recent report from the Testosterone Trials
(TTrials) group49 showed a signiﬁcantly greater increase
in coronary artery noncalciﬁed plaque volume among
older men with symptomatic hypogonadism treated
with testosterone gel for 1 year compared with pla-
cebo.49 However, none of these trials47–49 was designed
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Figure 1. Prevalence of total number of AHOs in TCS and other
malignant germ cell tumors with or without hypogonadism. TCS with
hypogonadism were more likely to report more AHOs compared
with those without. Chi-square test, P5.002.
Abbreviations: AHO, adverse health outcome; TCS, testicular cancer survivors.
Table 2. Multivariable Binary Logistic Regression
Analysis of Potential Risk Factors for
Hypogonadism in TCS and Other
Malignant GCTs
Variable OR 95% Cl P Valuea
Age at clinical evaluation, per 10 y 1.42 1.10–1.83 .006
Marital status
Married/Living as married — — Ref
Not married 0.79 0.50–1.25 .31
Tumor histology
Seminoma — — Ref
Nonseminoma/Mixed 0.79 0.48–1.31 .36
Body mass index
,25 kg/m2 — — Ref
25 to ,30 kg/m2 2.08 1.18–3.66 .011
$30 kg/m2 2.36 1.29–4.31 .005
Vigorous-intensity physical activity ($6 METs)
No — — Ref
Yes 0.66 0.41–1.04 .07
Cumulative number of risk alleles in rs6258 and rs12150660 (SHBG)
0 or 1 risk alleles — — Ref
2 or 3 risk alleles 1.45 0.95–2.24 .09
Abbreviations: GCT, germ cell tumor; METs, metabolic equivalents; OR,
odds ratio; TCS, testicular cancer survivors.
aBold indicates ORs with P,.05. For the multivariable binary logistic
regression analyses, 88 survivors were excluded due to unavailable data
for $1 variables.
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to prospectively assess adverse cardiovascular events,
and moreover, these ﬁndings may not apply to consider-
ably younger TCS. For young TCS with symptomatic
hypogonadism, testosterone replacement should be con-
sidered, and future research is needed to stringently
address both the beneﬁts and risks of testosterone re-
placement therapy. Two studies that examine the eﬀect
of testosterone replacement versus placebo on CVD
risk factors and various biomarkers have recently started
recruiting TCS in Europe (ClinicalTrials.gov identiﬁers:
NCT02991209 andNCT03339635). Although results of these
trials may provide some insights, the duration of each is
#12 months, and thus it is unlikely that they will be able to
provide information on the risk of CVD outcomes.
Strengths and Limitations
Strengths of our study include the large number of pa-
tients, detailedmedical chart abstraction, and evaluation
of several risk factors for hypogonadism, including ge-
netic variants. We also used a deﬁnition for hypo-
gonadism that is clinically relevant and easily applicable
to clinical practice. However, any cross-sectional design has
potential limitations anddoesnot allowus to infer causation
either of evaluated risk factors to hypogonadism or of
hypogonadism to associated AHOs. Although our investi-
gation included many AHOs, by design it was largely fo-
cused on cisplatin-related toxicities. Issues such as sexual
dysfunction and fertility will be investigated in additional
longitudinal follow-up of this cohort. Because blood
samples were collected at routine clinic visits, serum
testosterone levels weremeasured only once per patient
and did not always occur in the morning as per the
recommendation for testosterone testing. Although the
SNPs of interest were imputed and not genotyped, they
were in perfect linkage disequilibrium with a nearby
genotyped SNP.
Table 3. Associations Between AHOs and Hypogonadisma
AHO Status All Patients n (%)
Hypogonadism
P ValuebPresent, n %) Absent, n (%)
Hypercholesterolemia and on prescription
medication
Yes
No
56 (11.4)
432 (88.0)
38 (20.1)
151 (79.9)
18 (6.0)
281 (93.0) <.001
Hypertension and on prescription medication Yes
No
67 (13.6)
419 (85.3)
35 (18.5)
152 (80.4)
32 (10.6)
267 (88.4) .013
Erectile dysfunction Yes
No
73 (14.9)
413 (84.1)
37 (19.6)
149 (78.8)
36 (11.9)
264 (87.4) .018
Diabetes and on prescription medication Yes
No
19 (3.9)
458 (93.3)
11 (5.8)
170 (89.9)
8 (2.6)
288 (95.4) .07
Psychotropic prescription medications for
anxiety and/or depression
Yes
No
56 (11.4)
435 (88.6)
28 (14.8)
161 (85.2)
28 (9.3)
274 (90.7)
.06
Cardiovascular disease Yes
No
5 (1.0)
466 (94.9)
3 (1.6)
178 (94.2)
2 (0.7)
288 (95.4) .32
Peripheral vascular disease Yes
No
13 (2.6)
460 (93.7)
7 (3.7)
174 (92.1)
6 (2.0)
286 (94.7) .24
Thromboembolic disease Yes
No
4 (0.8)
469 (95.5)
1 (0.5)
180 (95.2)
3 (1.0)
289 (95.7) .58
Renal disease Yes
No
16 (3.3)
452 (92.1)
9 (4.8)
171 (90.5)
7 (2.3)
281 (93.0) .14
Peripheral neuropathy Yes
No
126 (25.7)
358 (72.9)
58 (30.7)
128 (67.7)
68 (22.5)
230 (76.2) .041
Raynaud phenomenon Yes
No
91 (18.5)
393 (80.0)
42 (22.2)
146 (77.2)
49 (16.2)
247 (81.8) .11
Benign thyroid disease Yes
No
11 (2.2)
462 (94.1)
4 (2.1)
177 (93.7)
7 (2.3)
285 (94.4) .90
Tinnitus Yes
No
170 (34.6)
317 (64.6)
66 (34.9)
122 (64.6)
104 (34.4)
195 (64.6) .94
Hearing impairment Yes
No
156 (31.8)
311 (63.3)
62 (32.8)
119 (63.0)
94 (31.1)
192 (63.6) .76
Problems with balance/vertigo/dizziness Yes
No
42 (8.6)
428 (87.2)
16 (8.5)
165 (87.3)
26 (8.6)
263 (87.1) .95
Abbreviation: AHO, adverse health outcome.
aDeﬁnitions for AHOs are shown in eTable 2. For some AHOs, data were not always available. Overall,,5% of survivors elected not to state whether they had$1 of
the AHOs; these data were excluded from P value calculations.
bChi-square test was used for calculation of P value. Bold indicates P value ,.05.
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Conclusions
At a relatively young age, there is a high prevalence of
hypogonadism among North American TCS treated with
modern cisplatin-based chemotherapy. Major risk factors
include increasing age and obesity. Hypogonadism was
strongly associated with risk factors for CVD. The clinical
value of assessing possible genetic variants in the role of
hypogonadism requires further study before these are rec-
ommended foruse in theclinic. In themeantime,TCS should
be encouraged to maintain a normal body weight and a
healthy lifestyle. Although there are currently no evidence-
based guidelines, Bhasin et al50 recommend that healthcare
providers screen for hypogonadism by surveying TCS for the
classic symptoms of hypogonadism (decreased energy, de-
pressed mood, decreased sexual desire and performance,
and night sweats)50 and prescribe testosterone replacement
therapy to survivors who have low testosterone levels on 2
occasions and have symptoms related to low testosterone.
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